U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula 2C24H26N2O4.H2O.2H3O4P
Molecular Weight 1026.9541
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARVEDILOL PHOSPHATE

SMILES

O.OP(O)(O)=O.OP(O)(O)=O.COC1=C(OCCNCC(O)COC2=CC=CC3=C2C4=C(N3)C=CC=C4)C=CC=C1.COC5=C(OCCNCC(O)COC6=CC=CC7=C6C8=C(N7)C=CC=C8)C=CC=C5

InChI

InChIKey=LHNYXTULDSJZRB-UHFFFAOYSA-N
InChI=1S/2C24H26N2O4.2H3O4P.H2O/c2*1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20;2*1-5(2,3)4;/h2*2-12,17,25-27H,13-16H2,1H3;2*(H3,1,2,3,4);1H2

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C24H26N2O4
Molecular Weight 406.4742
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Carvedilol competitively blocks β1, β2 and α1 receptors. The drug lacks sympathomimetic activity and has vasodilating properties that are exerted primarily through α1-blockade. Animal models indicate that carvedilol confers protection against myocardial necrosis, arrhythmia and cell damage caused by oxidising free radicals, and the drug has no adverse effects on plasma lipid profiles. COREG® (carvedilol) is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol is the first drug of its kind to be approved for the treatment of congestive heart failure, and is now the standard of care for this devastating disease. Carvedilol is also confirmed as effective in the management of mild to moderate hypertension and ischaemic heart disease.

Originator

Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/carvedilol.html

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
COREG

Approved Use

COREG® (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure). COREG is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

Launch Date

1995
Primary
COREG

Approved Use

COREG® (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure). COREG is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

Launch Date

1995
Primary
COREG

Approved Use

COREG® (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure). COREG is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

Launch Date

1995
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.4 ng/mL
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL, (+)- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
8.46 ng/mL
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL, (-)- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
26.5 ng/mL
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
94.3 ng × h/mL
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL, (+)- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
42.2 ng × h/mL
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL, (-)- plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
139 ng × h/mL
6.25 mg 2 times / day steady-state, oral
dose: 6.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CARVEDILOL plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Co-administed with::
lorazepam(7 mg)
Sources:
unknown, 41 years
n = 1
Health Status: unknown
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Other AEs: Wheezing...
Other AEs:
Wheezing (1 patient)
Sources:
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 66.7±12.0 years
n = 7
Health Status: unhealthy
Condition: chronic heart failure
Age Group: 66.7±12.0 years
Sex: M+F
Population Size: 7
Sources:
375 mg single, oral
Overdose
Dose: 375 mg
Route: oral
Route: single
Dose: 375 mg
Co-administed with::
simvastatin(fifteen 20-mg tablets)
Sources:
unhealthy, 84 years
n = 1
Health Status: unhealthy
Age Group: 84 years
Sex: M
Population Size: 1
Sources:
Other AEs: Hypotension...
Other AEs:
Hypotension (1 patient)
Sources:
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
n = 765
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Population Size: 765
Sources:
Disc. AE: Hypotension...
AEs leading to
discontinuation/dose reduction:
Hypotension (0.7%)
Sources:
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources: Page: p. 61
Disc. AE: Congestive cardiac failure...
AEs leading to
discontinuation/dose reduction:
Congestive cardiac failure (moderate, 1 patient)
Sources: Page: p. 61
25 mg 2 times / day steady, oral
Dose: 25 mg, 2 times / day
Route: oral
Route: steady
Dose: 25 mg, 2 times / day
Sources:
unhealthy, adult
n = 1156
Health Status: unhealthy
Condition: severe heart failure
Age Group: adult
Population Size: 1156
Sources:
Disc. AE: Dizziness...
AEs leading to
discontinuation/dose reduction:
Dizziness (1.3%)
Sources:
6.25 mg 2 times / day multiple, oral
Dose: 6.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6.25 mg, 2 times / day
Sources: Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources: Page: p. 61
Disc. AE: Abdominal distension...
AEs leading to
discontinuation/dose reduction:
Abdominal distension (1 patient)
Sources: Page: p. 61
6.25 mg 2 times / day multiple, oral
Dose: 6.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6.25 mg, 2 times / day
Sources: Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources: Page: p. 61
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (moderate, 1 patient)
Sources: Page: p. 61
AEs

AEs

AESignificanceDosePopulation
Wheezing 1 patient
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Co-administed with::
lorazepam(7 mg)
Sources:
unknown, 41 years
n = 1
Health Status: unknown
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Hypotension 1 patient
375 mg single, oral
Overdose
Dose: 375 mg
Route: oral
Route: single
Dose: 375 mg
Co-administed with::
simvastatin(fifteen 20-mg tablets)
Sources:
unhealthy, 84 years
n = 1
Health Status: unhealthy
Age Group: 84 years
Sex: M
Population Size: 1
Sources:
Hypotension 0.7%
Disc. AE
50 mg 1 times / day steady, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
n = 765
Health Status: unhealthy
Condition: heart failure
Age Group: adult
Population Size: 765
Sources:
Congestive cardiac failure moderate, 1 patient
Disc. AE
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources: Page: p. 61
Dizziness 1.3%
Disc. AE
25 mg 2 times / day steady, oral
Dose: 25 mg, 2 times / day
Route: oral
Route: steady
Dose: 25 mg, 2 times / day
Sources:
unhealthy, adult
n = 1156
Health Status: unhealthy
Condition: severe heart failure
Age Group: adult
Population Size: 1156
Sources:
Abdominal distension 1 patient
Disc. AE
6.25 mg 2 times / day multiple, oral
Dose: 6.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6.25 mg, 2 times / day
Sources: Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources: Page: p. 61
Rash moderate, 1 patient
Disc. AE
6.25 mg 2 times / day multiple, oral
Dose: 6.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6.25 mg, 2 times / day
Sources: Page: p. 61
unhealthy, adult
n = 54
Health Status: unhealthy
Age Group: adult
Population Size: 54
Sources: Page: p. 61
PubMed

PubMed

TitleDatePubMed
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.
1999
Statins and peripheral neuropathy.
1999 Jan
Carvedilol reduces ischaemic skeletal muscle necrosis.
1999 Sep
Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart.
2000
The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke.
2000 Aug
Beta-blockade in adriamycin-induced cardiomyopathy.
2000 Jun
Levosimendan.
2001
[Clinical efficacy of carvedilol in patients with severe cardiac insufficiency].
2001
Carvedilol as therapy in pediatric heart failure: an initial multicenter experience.
2001 Apr
Carvedilol--a new dimension in pediatric heart failure therapy.
2001 Apr
Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial.
2001 Feb
A placebo controlled evaluation of the antifibrillatory effects of carvedilol.
2001 Jan
Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study.
2001 Jan
Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial.
2001 Jan
Current role of beta-adrenergic blockers in the treatment of chronic congestive heart failure.
2001 Jan 15
Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228.
2001 Jan 15
Stereoselective effects of (R)- and (S)-carvedilol in humans.
2001 Jul
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.
2001 Jun
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
2001 Jun
A cost-effectiveness analysis of bisoprolol for heart failure.
2001 Jun
Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure.
2001 Jun
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.
2001 Jun
Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy.
2001 Jun 15
Nebivolol, carvedilol and metoprolol do not influence cardiac Ca(2+) sensitivity.
2001 Jun 22
Random research.
2001 Jun 26
[Adrenergic beta inhibitors in heart insufficiency: which and when?].
2001 Mar
Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade.
2001 Mar
Mechanisms of carvedilol action in human congestive heart failure.
2001 May
Carvedilol in the treatment of chronic heart failure.
2001 May
Expanding indications for beta-blockers in heart failure.
2001 May 31
Economic impact of beta blockade in heart failure.
2001 May 7
Patents

Sample Use Guides

Take with food. Individualize dosage and monitor during up-titration.• Heart failure: Start at 3.125 mg twice daily and increase to 6.25, 12.5, and then 25 mg twice daily over intervals of at least 2 weeks. Maintain lower doses if higher doses are not tolerated.• Left ventricular dysfunction following myocardial infarction: Start at 6.25 mg twice daily and increase to 12.5 mg then 25 mg twice daily afterintervals of 3 to 10 days. A lower starting dose or slower titration may be used.• Hypertension: Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg then 25 mg twice daily over intervals of 1 to 2 weeks.
Route of Administration: Oral
Compared with the PDGF-stimulated control, DNA synthesis decreased significantly to 60.3% +/- 10.4% and 18.3% +/- 5.9% in the presence of 1 and 10 microM of carvedilol, respectively (P < 0.05, each). Carvedilol significantly inhibited the activity of VSMCs stimulated by ET-1 and ANG-II. The IC50 of carvedilol was 1-10 microM. CsA only inhibited VSMCs significantly in the PDGF-stimulated subgroup. The addition of CsA in the presence of carvedilol did not affect the inhibitory activity of carvedilol. The pattern of inhibition in the combined group was uniform and similar to that of the carvedilol alone group, regardless of the stimulator used.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:42:48 GMT 2023
Edited
by admin
on Fri Dec 15 15:42:48 GMT 2023
Record UNII
EQT531S367
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARVEDILOL PHOSPHATE
ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
Carvedilol phosphate hemihydrate [WHO-DD]
Common Name English
SKF 105517D
Code English
CARVEDILOL PHOSPHATE HYDRATE [JAN]
Common Name English
CARVEDILOL DIHYDROGEN PHOSPHATE HEMIHYDRATE
Common Name English
CARVEDILOL PHOSPHATE HEMIHYDRATE
WHO-DD  
Common Name English
CARVEDILOL PHOSPHATE [VANDF]
Common Name English
2-PROPANOL, 1-(9H-CARBAZOL-4-YLOXY)-3-((2-(2-METHOXYPHENOXY)ETHYL)AMINO) , PHOSPHATE (SALT), HYDRATE (2:2:1)
Common Name English
COREG CR
Brand Name English
CARVEDILOL PHOSPHATE HYDRATE
JAN  
Common Name English
CARVEDILOL PHOSPHATE [USAN]
Common Name English
CARVEDILOL PHOSPHATE [ORANGE BOOK]
Common Name English
SKF-105517D
Code English
(2RS)-1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol phosphate salt (1:1) hemihydrate
Common Name English
SK&F-105517-D
Code English
Classification Tree Code System Code
NCI_THESAURUS C29576
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
Code System Code Type Description
DAILYMED
EQT531S367
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
PUBCHEM
11954344
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID60976535
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
DRUG BANK
DBSALT001201
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
SMS_ID
100000091219
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
CAS
610309-89-2
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
RXCUI
668310
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C65292
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
FDA UNII
EQT531S367
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
USAN
QQ-49
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
EVMPD
SUB25804
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
ChEMBL
CHEMBL723
Created by admin on Fri Dec 15 15:42:48 GMT 2023 , Edited by admin on Fri Dec 15 15:42:48 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY